Back to Merck

Merck News

MRK

Paul J. Diaz Joins Merck Board

Merck (MRK) elects Paul J. Diaz to its board, effective Nov 1, 2026. Investors should note timing amid Keytruda concentration, Cidara deal and recent debt activity.

MRK

Merck Closes $6B Multi-Maturity Notes — MRK Bonds

Merck (MRK) completed a $6B multi-maturity notes offering with maturities 2028–2056 on May 22, 2026. Terms, capital-structure context and investor considerations.

MRK

Merck Closes $7.25B Multi-Series Notes

Dec 4, 2025 — Merck (MRK) closes $7.25B multi-series notes offering with maturities through 2065, adjusting its debt profile and extending long-term funding.

MRK

Merck Q3 2025 Filing: No Strategy Shift (MRK)

Merck's Q3 2025 filing confirms no material strategic changes. Keytruda remains dominant; financials and debt activity also highlighted for investors.

MRK

Merck Q3 2025: Key Events Impact Valuation

Merck (MRK) Q3 2025: 4% sales growth, new FDA approvals and raised EPS guidance. Analysis of Keytruda concentration, cash flow, debt and valuation implications.

MRK

Merck Raises 2025 EPS & Sales Guidance

Merck (MRK) narrows and raises its 2025 EPS and sales outlook. 9M results, Keytruda strength and cash flow underpin the revision; concentration risks remain.

MRK

MRK: FDA Approvals & Verona Pharma Acquisition

Merck (MRK) wins FDA approval for Keytruda Qlex and Winrevair; completes Verona Pharma acquisition for ensifentrine (Ohtuvayre). Investor implications and financial context.

MRK

Merck Q3 2025: Revenue Up 4%, Net Income +83%

Merck (MRK) reports Q3 2025 sales growth of 4% and an 83% jump in net income. Analysis of product drivers, cash flow, debt and investor watchpoints.

MRK

Merck Closes $6.5B Multi-Series Notes (MRK)

Merck (MRK) closed a $6.5B multi-series notes offering on Sep 9, 2025, with maturities from 2027 to 2055 and varied coupons for investors to consider.